- Home
- TTGT vs OVID Comparison
TTGT vs OVID Comparison
Compare TTGT & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | OVID |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.2M | 365.5M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TTGT | OVID |
|---|---|---|
| Price | $4.26 | $2.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $10.75 | $4.60 |
| AVG Volume (30 Days) | 305.0K | ★ 4.6M |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $2.75 | $22.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $3.41 | $0.27 |
| 52 Week High | $9.00 | $3.11 |
Technical Indicators
Market Signals| Indicator | TTGT | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 64.63 |
| Support Level | $3.49 | $1.31 |
| Resistance Level | $4.75 | $3.11 |
| Average True Range (ATR) | 0.32 | 0.22 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 62.20 | 72.81 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.